Aerami Therapeutics terminated its merger with FoxWayne Enterprises Acquisition in a $250m deal.

Aerami Therapeutics, a developer of therapies intended for the treatment of severe respiratory and chronic diseases, terminated its merger with FoxWayne Enterprises Acquisition in a $250m deal. Aerami and FoxWayne believe that terminating the business combination agreement is the best path forward for the parties and their respective stockholders.